Supplemental figure for"Extended treatment of Abrocitinib: evaluation of efficacy and safety in chronic actinic dermatitis"

NIAID Data Ecosystem2026-05-01 收录

慢性光化性皮炎治疗

药物疗效安全性

数据链接：

https://data.mendeley.com/datasets/m3n8kstyh3 数据链接链接失效反馈

官方服务：

资源简介：

Supplemental figure for"Extended treatment of Abrocitinib: evaluation of efficacy and safety in chronic actinic dermatitis"

创建时间：

2024-01-18

Supplementary Material for: Balancing efficacy and tolerability of first-line systemic therapies for advanced hepatocellular carcinoma: a network metanalysis

晚期肝癌治疗优化

药物疗效安全性

Background: Atezolizumab+Bevacizumab represents the current standard of care for first-line treatment of advanced HCC. However, direct comparison with other combination treatments including immune-che

Mendeley Data2024-06-25 更新70

Supplementary Material for: Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies

肾性贫血治疗

药物疗效安全性

Background: Molidustat, a novel hypoxia-inducible factor-prolyl hydroxylase inhibitor, is being investigated for the treatment of anemia associated with chronic kidney disease (CKD). The efficacy and

Figshare2019-03-08 更新40

Dataset from Phase II Evaluation of Safety, Tolerability, and Efficacy of BI 730357 in Patients With Moderate-to-severe Plaque Psoriasis

银屑病药物临床试验

药物疗效安全性

The primary objective is based on Week 12 co-primary endpoints of PASI (Psoriasis Area and Severity Index) 75 and sPGA (Static Physician's Global Assessment) 0/1, and overall safety Secondary objectiv

NIAID Data Ecosystem20

RE covery and SUR vival of patients with moderate to severe acute RE spiratory distress syndrome (ARDS) due to C OVID-19: a multicenter, single-arm, Phase IV itolizumab T rial: RESURRECT

COVID-19治疗

药物疗效安全性

Itolizumab, an anti-CD6 monoclonal antibody, down-regulates COVID-19-mediated inflammation and the acute effects of cytokine release syndrome. This study aimed to evaluate the safety and efficacy of i

DataCite Commons2024-08-09 更新50

Data_Sheet_1_Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials.ZIP

射血分数保留心力衰竭治疗

药物疗效安全性

AimsThe efficacy and safety of sacubitril/valsartan for patients with heart failure with preserved ejection fraction (HFpEF) are controversial. Hence, the primary objective of the study was to evaluat

NIAID Data Ecosystem40

Supplemental figure for"Extended treatment of Abrocitinib: evaluation of efficacy and safety in chronic actinic dermatitis"

资源简介：

相关数据集